31
Participants
Start Date
March 23, 2011
Primary Completion Date
October 22, 2019
Study Completion Date
October 22, 2019
LCI699
Osilodrostat 1 mg and 5 mg capsules, was prepared by Novartis and supplied to the Investigator. The capsule formulation of osilodrostat was later changed to tablets and this change was implemented in the study with Protocol amendment 6. Osilodrostat was open labeled 1 mg, 5 mg, 10 mg and 20 mg tablets.
Cleveland Clinic Foundation, Cleveland
Novartis Investigative Site, Paris
Novartis Investigative Site, Napoli
Novartis Investigative Site, Le Kremlin-Bicêtre
Northwestern University Endo, Metabolism and Molecular, Chicago
Massachusetts General Hospital Neuroendocrine Unit, Boston
Oregon Health and Science University SC, Portland
Novartis Investigative Site, Ancona
Novartis Investigative Site, Sapporo
Novartis Investigative Site, Chiba
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY